Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893762 | 0.85 | LMNA (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL3887891 | 0.81 | ACHE (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL3885591 | 0.80 | ACHE (0.35) | LMNAALDH1A1 | |
| SCHEMBL3883878 | 0.80 | MEN1 (0.31) | — | |
| SCHEMBL18848363 | 0.78 | ALDH1A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL18848221 | 0.78 | ALDH1A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL18848280 | 0.78 | ALDH1A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL1884602 | 0.77 | LMNA (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL1883974 | 0.77 | ALDH1A1 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4LMNA | |
| SCHEMBL3891108 | 0.77 | LMNA (0.33) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566738-B2 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | XENOPORT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | ASS1, APEH, ACMSD | CHRNB2 2556/4885CHRNB4 3148/4885CHRNA3 1286/4885 |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | ASS1, APEH, ACMSD | CHRNB2 2556/4885CHRNB4 3148/4885CHRNA3 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.